Slevin F, Zattoni F, Checcucci E, Cumberbatch MGK, Nacchia A, Cornford P, Briers E, De Meerleer G, De Santis M, Eberli D, Gandaglia G, Gillessen S, Grivas N, Liew M, Linares Espinós EE, Oldenburg J, Oprea-Lager DE, Ploussard G, Rouvière O, Schoots IG, Smith EJ, Stranne J, Tilki D, Smith CT, Van Den Bergh RCN, Van Oort IM, Wiegel T, Yuan CY, Van den Broeck T, Henry AM.
A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer. Eur Urol Oncol. 2024 Aug;7(4):677-696. doi: 10.1016/j.euo.2023.11.018. Epub 2023 Dec 26. PMID: 38151440

Preisser F, Abrams-Pompe RS, Stelwagen PJ, Böhmer D, Zattoni F, Magli A, Rivas JG, Dilme RV, Sepulcri M, Eguibar A, Heidegger I, Arnold C, Fankhauser CD, Chun FK, van der Poel H, Gandaglia G, Wiegel T, van den Bergh RCN, Tilki D; EAU-YAU Prostate Cancer Working Group.
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
Eur Urol. 2024 Feb;85(2):164-170. doi: 10.1016/j.eururo.2023.05.038. Epub 2023 Jun 22. PMID: 37355358

Adebahr S, Althaus A, Scharl S, Strouthos I, Farolfi A, Serani F, Lanzafame H, Trapp C, Koerber SA, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Grosu AL, Kroeze SGC, Guckenberger M, Fanti S, Hruby G, Emmett L, Belka C, Schmidt-Hegemann NS, Henkenberens C, Aebersold DM, Wiegel T, Afshar-Oromieh A, Zamboglou C, Shelan M.
The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):558-567. doi: 10.1007/s00259-023-06438-3. Epub 2023 Sep 22. PMID: 37736808

Kowalski C, Sibert NT, Hammerer P, Wesselmann S, Feick G, Carl EG, Klotz T, Apel H, Dieng S, Nyarangi-Dix J, Knoll T, Reike MJ, Duwe G, Bartolf E, Steiner T, Borowitz R, Lümmen G, Seitz AK, Pfitzenmaier J, Aziz A, Brock M, Berger FP, Kaftan BT, Grube C, Häfner T, Hamza A, Schmelz H, Haas J, Lenart S, Lafita A, Sippel C, Winter A, Kedia G, Hadaschik B, Varga Z, Buse S, Richter M, Distler F, Simon J, Wiegel T, Baltes S, Janitzky A, Sommer JP, Hijazi S, Fülkell P, Harke NN, Bolenz C, Khalil C, Breidenbach C, Tennstedt P, Burchardt M.
Harninkontinenz nach radikaler Prostatektomie beim Prostatakarzinom – aktuelle Daten von 17.149 Patienten aus 125 zertifizierten Zentren [Urinary incontinence after radical prostatectomy for prostate cancer-data from 17,149 patients from 125 certified centers]. Urologie. 2024 Jan;63(1):67-74. doi: 10.1007/s00120-023-02197-z. Epub 2023 Sep 25. PMID: 37747493

Koerber SA, Höcht S, Aebersold D, Albrecht C, Boehmer D, Ganswindt U, Schmidt-Hegemann NS, Hölscher T, Mueller AC, Niehoff P, Peeken JC, Pinkawa M, Polat B, Spohn SKB, Wolf F, Zamboglou C, Zips D, Wiegel T.
Prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? : Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO). Strahlenther Onkol. 2024 Mar;200(3):181-187. doi: 10.1007/s00066-023-02193-4. Epub 2024 Jan 25. PMID: 38273135
                                                                                                                                         
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders GJLH, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouvière O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM, Tilki D.
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024 Aug;86(2):148-163. doi: 10.1016/j.eururo.2024.03.027. Epub 2024 Apr 13. PMID: 38614820.

Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, J L H van Leenders G, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouvière O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM, Cornford P.
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024 Aug;86(2):164-182. doi: 10.1016/j.eururo.2024.04.010. Epub 2024 Apr 29. PMID: 38688773.

Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Koerber SA, Debus J, Peeken JC, Vogel MME, Kroeze SGC, Guckenberger M, Krafcsik M, Hruby G, Emmett L, Schmidt-Hegemann NS, Trapp C, Spohn SKB, Henkenberens C, Mayer B, Shelan M, Aebersold DM, Thamm R, Wiegel T.
European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy. Radiother Oncol. 2024 May;194:110215. doi: 10.1016/j.radonc.2024.110215. Epub 2024 Mar 7. PMID: 38458259.

Sabbagh A, Tilki D, Feng J, Huland H, Graefen M, Wiegel T, Böhmer D, Hong JC, Valdes G, Cowan JE, Cooperberg M, Feng FY, Mohammad T, Shelan M, D'Amico AV, Carroll PR, Mohamad O.
Multi-institutional Development and External Validation of a Machine Learning Model for the Prediction of Distant Metastasis in Patients Treated by Salvage Radiotherapy for Biochemical Failure After Radical Prostatectomy. Eur Urol Focus.2024 Jan;10(1):66-74.doi:10.1016/j.euf.2023.07. 004. Epub 2023 Jul 26. PMID: 37507248.

Schwanke D, Schüle S, Stewart S, Fatanmi OO, Wise SY, Hackenbroch C, Wiegel T, Singh VK, Port M, Abend M, Ostheim P.
Validating a Four-gene Set for H-ARS Severity Prediction in Peripheral Blood Samples of Irradiated Rhesus Macaques.
Radiat Res. 2024 May 1;201(5):504-513. doi: 10.1667/RADE-23-00162.1. PMID: 38471521.

Schwanke D, Fatanmi OO, Wise SY, Ostheim P, Schüle S, Kaletka G, Stewart S, Wiegel T, Singh VK, Port M, Abend M.
Validating Radiosensitivity with Pre-Exposure Differential Gene Expression in Peripheral Blood Predicting Survival and Non-Survival in a Second Irradiated Rhesus Macaque Cohort.
Radiat Res. 2024 May 1;201(5):384-395. doi: 10.1667/RADE-23-00099.1. PMID: 38282135.

Trapp C, Aebersold DM, Belka C, Casuscelli J, Emmett L, Eze C, Fanti S, Farolfi A, Fendler W, Grosu AL, Guckenberger M, Hruby G, Kirste S, Koerber SA, Kroeze S, Peeken JC, Rogowski P, Scharl S, Shelan M, Spohn SKB, Strouthos I, Unterrainer L, Vogel M, Wiegel T, Zamboglou C, Schmidt-Hegemann NS. Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis.
Eur J Nucl Med Mol Imaging. 2024 Jun 28. doi: 10.1007/s00259-024-06802-x. Epub ahead of print. PMID: 38940843.

Höcht S, Böhmer D, Wiegel T, Ganswindt U; AG Prostata der Deutschen Gesellschaft für Radioonkologie.
Ultrahypofraktionierte Radiotherapie beim Prostatakarzinom – ein neuer Standard? [Ultrahpyofractionated radiotherapy for prostate cancer-a new standard?].
Urologie. 2023 Mar;62(3):299-301. German. doi: 10.1007/s00120-023-02049-w. Epub 2023 Feb 28. PMID: 36853507.

Marra G, van Leenders GJLH, Zattoni F, Kesch C, Rajwa P, Cornford P, van der Kwast T, van den Bergh RCN, Briers E, Van den Broeck T, De Meerleer G, De Santis M, Eberli D, Farolfi A, Gillessen S, Grivas N, Grummet JP, Henry AM, Lardas M, Lieuw M, Linares Espinós E, Mason MD, O'Hanlon S, van Oort IM, Oprea-Lager DE, Ploussard G, Rouvière O, Schoots IG, Stranne J, Tilki D, Wiegel T, Willemse PM, Mottet N, Gandaglia G; European Association of Urology Young Academic Urologists Prostate Cancer Working Group, the EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines Panel on Prostate Cancer.
Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review.
Eur Urol. 2023 Apr 27:S0302-2838(23)02654-4. doi: 10.1016/j.eururo.2023.03.014. Epub ahead of print. PMID: 37117107.

Solomonidou N, Germanou D, Strouthos I, Karagiannis E, Farolfi A, Koerber SA, Debus J, Peeken JC, Vogel ME, Vrachimis A, Spohn SKB, Shelan M, Aebersold D, Grosu AL, Ceci F, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Hruby G, Scharl S, Wiegel T, Bartenstein P, Henkenberens C, Emmett L, Schmidt-Hegemann NS, Ferentinos K, Zamboglou C.
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
Eur J Nucl Med Mol Imaging. 2023 Mar 11. doi: 10.1007/s00259-023-06185-5. Epub ahead of print. PMID: 36905411.

Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Lanzafame H, Giuseppe Morganti A, Trapp C, Koerber SA, Debus J, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Ruf J, Grosu AL, Ceci F, Fendler WP, Bartenstein P, Kroeze SGC, Guckenberger M, Krafcsik M, Klopscheck C, Fanti S, Hruby G, Emmett L, Belka C, Stief C, Schmidt-Hegemann NS, Henkenberens C, Mayer B, Miksch J, Shelan M, Aebersold DM, Thamm R, Wiegel T.
Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study.
Radiother Oncol. 2023 May 3;184:109678. doi: 10.1016/j.radonc.2023.109678. Epub ahead of print. PMID: 37146766.

Schmidt-Hegemann NS, Zamboglou C, Mason M, Mottet N, Hinnen K, De Meerleer G, Cozzarini C, Maingon P, Henry A, Spahn M, Cornford P, Belka C, Wiegel T.
ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer.
Radiother Oncol. 2023 Feb 20;183:109544. doi: 10.1016/j.radonc.2023.109544. Epub ahead of print. PMID: 36813168.

Sabbagh A, Washington SL 3rd, Tilki D, Hong JC, Feng J, Valdes G, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Cowan JE, Cooperberg M, Feng FY, Roach M 3rd, Trock BJ, Partin AW, D'Amico AV, Carroll PR, Mohamad O.
Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer.
Eur Urol Oncol. 2023 Mar 1:S2588-9311(23)00038-X. doi: 10.1016/j.euo.2023.02.006. Epub ahead of print. PMID: 36868922.

Dal Pra A, Dirix P, Khoo V, Carrie C, Cozzarini C, Fonteyne V, Ghadjar P, Gomez-Iturriaga A, Panebianco V, Zapatero A, Bossi A, Wiegel T.
ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer.
Clin Transl Radiat Oncol. 2023 May 9;41:100638. doi: 10.1016/j.ctro.2023.100638. PMID: 37251620; PMCID: PMC10209331.

Preisser F, Abrams-Pompe RS, Stelwagen PJ, Böhmer D, Zattoni F, Magli A, Rivas JG, Dilme RV, Sepulcri M, Eguibar A, Heidegger I, Arnold C, Fankhauser CD, Chun FK, van der Poel H, Gandaglia G, Wiegel T, van den Bergh RCN, Tilki D; EAU-YAU Prostate Cancer Working Group.
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
Eur Urol. 2023 Jun 22:S0302-2838(23)02886-5. doi: 10.1016/j.eururo.2023.05.038. Epub ahead of print. PMID: 37355358.

Sabbagh A, Tilki D, Feng J, Huland H, Graefen M, Wiegel T, Böhmer D, Hong JC, Valdes G, Cowan JE, Cooperberg M, Feng FY, Mohammad T, Shelan M, D'Amico AV, Carroll PR, Mohamad O.
Multi-institutional Development and External Validation of a Machine Learning Model for the Prediction of Distant Metastasis in Patients Treated by Salvage Radiotherapy for Biochemical Failure After Radical Prostatectomy.
Eur Urol Focus. 2023 Jul 26:S2405-4569(23)00176-1. doi: 10.1016/j.euf.2023.07.004. Epub ahead of print. PMID: 37507248.

Thaiss W, Zengerling F, Friedrich J, Hechler V, Grunert M, Bolenz C, Wiegel T, Beer AJ, Prasad V. Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre.
Cancers (Basel). 2023 Jun 16;15(12):3216. doi: 10.3390/cancers15123216. PMID: 37370826; PMCID: PMC10296825.

Dirix P, Dal Pra A, Khoo V, Carrie C, Cozzarini C, Fonteyne V, Ghadjar P, Gomez-Iturriaga A, Schmidt-Hegemann NS, Panebianco V, Zapatero A, Bossi A, Wiegel T.
ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy.
Clin Transl Radiat Oncol. 2023 Sep 23;43:100684. doi: 10.1016/j.ctro.2023.100684. PMID: 37808453; PMCID: PMC10556584.

Spohn SKB, Draulans C, Kishan AU, Spratt D, Ross A, Maurer T, Tilki D, Berlin A, Blanchard P, Collins S, Bronsert P, Chen R, Pra AD, de Meerleer G, Eade T, Haustermans K, Hölscher T, Höcht S, Ghadjar P, Davicioni E, Heck M, Kerkmeijer LGW, Kirste S, Tselis N, Tran PT, Pinkawa M, Pommier P, Deltas C, Schmidt-Hegemann NS, Wiegel T, Zilli T, Tree AC, Qiu X, Murthy V, Epstein JI, Graztke C, Gao X, Grosu AL, Kamran SC, Zamboglou C.
Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus.
Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):503-520. doi: 10.1016/j.ijrobp.2022.12.038. Epub 2022 Dec 31. PMID: 36596346.
Adebahr S, Althaus A, Scharl S, Strouthos I, Farolfi A, Serani F, Lanzafame H, Trapp C, Koerber SA, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Grosu AL, Kroeze SGC, Guckenberger M, Fanti S, Hruby G, Emmett L, Belka C, Schmidt-Hegemann NS, Henkenberens C, Aebersold DM, Wiegel T, Afshar-Oromieh A, Zamboglou C, Shelan M.
The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
Eur J Nucl Med Mol Imaging. 2023 Sep 22. doi: 10.1007/s00259-023-06438-3. Epub ahead of print. PMID: 37736808.

Kowalski C, Sibert NT, Hammerer P, Wesselmann S, Feick G, Carl EG, Klotz T, Apel H, Dieng S, Nyarangi-Dix J, Knoll T, Reike MJ, Duwe G, Bartolf E, Steiner T, Borowitz R, Lümmen G, Seitz AK, Pfitzenmaier J, Aziz A, Brock M, Berger FP, Kaftan BT, Grube C, Häfner T, Hamza A, Schmelz H, Haas J, Lenart S, Lafita A, Sippel C, Winter A, Kedia G, Hadaschik B, Varga Z, Buse S, Richter M, Distler F, Simon J, Wiegel T, Baltes S, Janitzky A, Sommer JP, Hijazi S, Fülkell P, Harke NN, Bolenz C, Khalil C, Breidenbach C, Tennstedt P, Burchardt M.  
Harninkontinenz nach radikaler Prostatektomie beim Prostatakarzinom – aktuelle Daten von 17.149 Patienten aus 125 zertifizierten Zentren [Urinary incontinence after radical prostatectomy for prostate cancer-data from 17,149 patients from 125 certified centers].                                        
Urologie. 2023 Sep 25. German. doi: 10.1007/s00120-023-02197-z. Epub ahead of print. PMID: 37747493.

Zamboglou C, Peeken JC, Janbain A, Katsahian S, Strouthos I, Ferentinos K, Farolfi A, Koerber SA, Debus J, Vogel ME, Combs SE, Vrachimis A, Morganti AG, Spohn SKB, Shelan M, Aebersold DM, Grosu AL, Ceci F, Henkenberens C, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Bartenstein P, Hruby G, Scharl S, Wiegel T, Emmett L, Arnoux A, Schmidt-Hegemann NS.                                                             
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer.                                                                             
JAMA Netw Open. 2023 May 1;6(5):e2314748. doi: 10.1001/jamanetworkopen.2023.14748. PMID: 37219907; PMCID: PMC10208140.

Willemse PM, Davis NF, Grivas N, Zattoni F, Lardas M, Briers E, Cumberbatch MG, De Santis M, Dell'Oglio P, Donaldson JF, Fossati N, Gandaglia G, Gillessen S, Grummet JP, Henry AM, Liew M, MacLennan S, Mason MD, Moris L, Plass K, O'Hanlon S, Omar MI, Oprea-Lager DE, Pang KH, Paterson CC, Ploussard G, Rouvière O, Schoots IG, Tilki D, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TBL. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
Eur Urol. 2022 Apr;81(4):337-346. doi: 10.1016/j.eururo.2021.12.007.

Merzenich H, Baaken D, Schmidt M, Bekes I, Schwentner L, Janni W, Woeckel A, Bartkowiak D, Wiegel T, Blettner M, Wollschläger D, Schmidberger H. Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa).
Breast Cancer Res Treat. 2022 Jan;191(1):147-157. doi: 10.1007/s10549-021-06412-3.

Dapper H, Belka C, Bock F, Budach V, Budach W, Christiansen H, Debus J, Distel L, Dunst J, Eckert F, Eich H, Eicheler W, Engenhart-Cabillic R, Fietkau R, Fleischmann DF, Frerker B, Giordano FA, Grosu AL, Herfarth K, Hildebrandt G, Kaul D, Kölbl O, Krause M, Krug D, Martin D, Matuschek C, Medenwald D, Nicolay NH, Niewald M, Oertel M, Petersen C, Pohl F, Raabe A, Rödel C, Rübe C, Schmalz C, Schmeel LC, Steinmann D, Stüben G, Thamm R, Vordermark D, Vorwerk H, Wiegel T, Zips D, Combs SE. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations : An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO).
Strahlenther Onkol. 2022 Jan;198(1):1-11. doi: 10.1007/s00066-021-01861-7. Epub 2021 Nov 16.

Böhmer D, Siegmann A, Scharl S, Ruf C, Wiegel T, Krafcsik M, Thamm R.
Impact of Dose Escalation on the Efficacy of Salvage Radiotherapy for Recurrent Prostate Cancer-A Risk-Adjusted, Matched-Pair Analysis.
Cancers (Basel). 2022 Mar 4;14(5):1320. doi: 10.3390/cancers14051320.

Tilki D, Preisser F, Thamm R, Pompe RS, Chun FK, Graefen M, Siegmann A, Böhmer D, Budach V, Wiegel T.
Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis.
 Cancers (Basel). 2022 Jan 31;14(3):740. doi: 10.3390/cancers14030740

Spohn SKB, Adebahr S, Huber M, Jenkner C, Wiehle R, Nagavci B, Schmucker C, Carl EG, Chen RC, Weber WA, Mix M, Rühle A, Sprave T, Nicolay NH, Gratzke C, Benndorf M, Wiegel T, Weis J, Baltas D, Grosu AL, Zamboglou C.
Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients.
BMC Cancer. 2022 Mar 28;22(1):337. doi: 10.1186/s12885-022-09434-2.

Lingl JP, Böhm F, Wiegel T, Beer AJ, Hoffmann TK.  
PSMA-PET-MRI and radio-guided surgery in cervical lymphadenectomy.
HNO. 2022 Dec;70(12):907-910. German. doi: 10.1007/s00106-022-01197-3

Müller AC, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Ghadjar P, Schmidt-Hegemann NS, Höcht S, Hölscher T, Niehoff P, Pinkawa M, Sedlmayer F, Wolf F, Zamboglou C, Zips D, Wiegel T; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO).
Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases.
Strahlenther Onkol. 2022 Aug;198(8):683-689. doi: 10.1007/s00066-022-01961-y

Ghadjar P, Koerber SA, Hölscher T, Höcht S, Wiegel T.
The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy.
Lancet. 2022 Sep 17;400(10356):883-884. doi: 10.1016/S0140-6736(22)01440-4

Wegener D, Aebersold DM, Grimm MO, Hammerer P, Froehner M, Graefen M, Boehmer D, Zips D, Wiegel T.
Postoperative Radiotherapy of Prostate Cancer: Adjuvant versus Early Salvage.
Biomedicines. 2022 Sep 12;10(9):2256. doi: 10.3390/biomedicines10092256

Spohn SKB, Draulans C, Kishan AU, Spratt D, Ross A, Maurer T, Tilki D, Berlin A, Blanchard P, Collins S, Bronsert P, Chen R, Pra AD, de Meerleer G, Eade T, Haustermans K, Hölscher T, Höcht S, Ghadjar P, Davicioni E, Heck M, Kerkmeijer LGW, Kirste S, Tselis N, Tran PT, Pinkawa M, Pommier P, Deltas C, Schmidt-Hegemann NS, Wiegel T, Zilli T, Tree AC, Qiu X, Murthy V, Epstein JI, Graztke C, Gao X, Grosu AL, Kamran SC, Zamboglou C.
Genomic classifiers in personalized prostate cancer radiotherapy approaches - a systematic review and future perspectives based on international consensus.
Int J Radiat Oncol Biol Phys. 2022 Dec 31:S0360-3016(22)03691-4. doi: 10.1016/j.ijrobp.2022.12.038

Baaken D, Merzenich H, Schmidt M, Bekes I, Schwentner L, Janni W, Wöckel A, Mayr M, Mose S, Merz T, Ghilescu V, Renner J, Bartkowiak D, Wiegel T, Blettner M, Schmidberger H, Wollschläger D.
A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany.
Breast. 2022 Oct;65:1-7. doi: 10.1016/j.breast.2022.05.007

Aicher A, Sindrilaru A, Crisan D, Thaiss W, Steinacker J, Beer M, Wiegel T, Scharffetter-Kochanek K, Beer AJ, Prasad V.
Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma.
Pharmaceutics. 2022 Jul 14;14(7):1466. doi: 10.3390/pharmaceutics14071466

Zamboglou C, Strouthos I, Sahlmann J, Farolfi A, Serani F, Medici F, Cavallini L, Morganti AG, Trapp C, Koerber SA, Peeken JC, Vogel MME, Schiller K, Combs SE, Eiber M, Vrachimis A, Ferentinos K, Spohn SKB, Kirste S, Gratzke C, Ruf J, Grosu AL, Ceci F, Fendler WP, Miksch J, Kroeze S, Guckenberger M, Lanzafame H, Fanti S, Hruby G, Wiegel T, Emmett L, Schmidt-Hegemann NS, Henkenberens C. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy.
Int J Radiat Oncol Biol Phys. 2022 Aug 1;113(5):1015-1024. doi: 10.1016/j.ijrobp.2022.04.048

Moris L, Gandaglia G, Vilaseca A, Van den Broeck T, Briers E, De Santis M, Gillessen S, Grivas N, O'Hanlon S, Henry A, Lam TB, Lardas M, Mason M, Oprea-Lager D, Ploussard G, Rouviere O, Schoots IG, van der Poel H, Wiegel T, Willemse PP, Yuan CY, Grummet JP, Tilki D, van den Bergh RCN, Cornford P, Mottet N.
Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review.
Eur Urol Focus. 2022 May;8(3):690-700. doi: 10.1016/j.euf.2021.05.009.

Lardas M, Grivas N, Debray TPA, Zattoni F, Berridge C, Cumberbatch M, Van den Broeck T, Briers E, De Santis M, Farolfi A, Fossati N, Gandaglia G, Gillessen S, O'Hanlon S, Henry A, Liew M, Mason M, Moris L, Oprea-Lager D, Ploussard G, Rouviere O, Schoots IG, van der Kwast T, van der Poel H, Wiegel T, Willemse PP, Yuan CY, Grummet JP, Tilki D, van den Bergh RCN, Lam TB, Cornford P, Mottet N. Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.          Eur Urol Focus. 2022 May;8(3):674-689. doi: 10.1016/j.euf.2021.04.020

Böhmer D, Wiegel T, Höcht S, Ganswindt U; AG Prostata der Deutschen Gesellschaft für Radioonkologie.
Bedeutung der Dauer einer begleitenden Hormontherapie zur definitiven Strahlentherapie [Significance of duration of concurrent hormone therapy and definitive radiotherapy].
Urologie. 2022 Dec;61(12):1387-1389. German. doi: 10.1007/s00120-022-01960-y. Epub 2022 Oct 19. PMID: 36260116.

Wolf F, Sedlmayer F, Aebersold D, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Ghadjar P, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Schmidt-Hegemann NS, Zamboglou C, Zips D, Wiegel T. Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer.
Strahlenther Onkol. 2021 Feb;197(2):89-96. doi: 10.1007/s00066-020-01723-8. Epub 2020 Dec 10.

Ploussard G, Fossati N, Wiegel T, D'Amico A, Hofman MS, Gillessen S, Mottet N, Joniau S, Spratt DE. Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature.
Eur Urol Oncol. 2021 Apr;4(2):150-169. doi: 10.1016/j.euo.2021.01.001. Epub 2021 Feb 8.

Prasad V, Zengerling F, Steinacker JP, Bolenz C, Beer M, Wiegel T, Eiber M, Fleshner N, Beer AJ.      First Experiences with 177Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients.
 J Nucl Med. 2021 Jul 1;62(7):975-978. doi: 10.2967/jnumed.120.249029. Epub 2020 Nov 27.

Van den Broeck T, Oprea-Lager D, Moris L, Kailavasan M, Briers E, Cornford P, De Santis M, Gandaglia G, Gillessen Sommer S, Grummet JP, Grivas N, Lam TBL, Lardas M, Liew M, Mason M, O'Hanlon S, Pecanka J, Ploussard G, Rouviere O, Schoots IG, Tilki D, van den Bergh RCN, van der Poel H, Wiegel T, Willemse PP, Yuan CY, Mottet N.
A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer.
Eur Urol. 2021 Nov;80(5):531-545. doi: 10.1016/j.eururo.2021.04.028. Epub 2021 May 5

Lardas M, Grivas N, Debray TPA, Zattoni F, Berridge C, Cumberbatch M, Van den Broeck T, Briers E, De Santis M, Farolfi A, Fossati N, Gandaglia G, Gillessen S, O'Hanlon S, Henry A, Liew M, Mason M, Moris L, Oprea-Lager D, Ploussard G, Rouviere O, Schoots IG, van der Kwast T, van der Poel H, Wiegel T, Willemse PP, Yuan CY, Grummet JP, Tilki D, van den Bergh RCN, Lam TB, Cornford P, Mottet N. Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2021 May 6:S2405-4569(21)00126-7. doi: 10.1016/j.euf.2021.04.020.

Moris L, Gandaglia G, Vilaseca A, Van den Broeck T, Briers E, De Santis M, Gillessen S, Grivas N, O'Hanlon S, Henry A, Lam TB, Lardas M, Mason M, Oprea-Lager D, Ploussard G, Rouviere O, Schoots IG, van der Poel H, Wiegel T, Willemse PP, Yuan CY, Grummet JP, Tilki D, van den Bergh RCN, Cornford P, Mottet N.
Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review.
Eur Urol Focus. 2021 Jun 16:S2405-4569(21)00161-9. doi: 10.1016/j.euf.2021.05.009.

Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M.
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
J Cancer Res Clin Oncol. 2021 Jan;147(1):235-242. doi: 10.1007/s00432-020-03327-2. Epub 2020 Sep 4

Albers P, Wiegel T, Schmidberger H, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Meisner C, Wellek S, Grozinger K, Renner P, Burmester M, Schneider F, Stöckle M. World Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial.
J Urol. 2021 Jan;39(1):65-72. doi: 10.1007/s00345-020-03154-7.

Ghadjar P, Höcht S, Wiegel T.
Postoperative radiotherapy in prostate cancer.
Lancet. 2021 May 1;397(10285):1623. doi: 10.1016/S0140-6736(21)00273-7.

Tilki D, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Mohamad O, Cowan JE, Feng FY, Carroll PR, Trock BJ, Partin AW, D'Amico AV.
Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death.
J Clin Oncol. 2021 Jul 10;39(20):2284-2293. doi: 10.1200/JCO.20.03714. Epub 2021 Jun 4

Pinkawa M, Aebersold DM, Böhmer D, Flentje M, Ghadjar P, Schmidt-Hegemann NS, Höcht S, Hölscher T, Müller AC, Niehoff P, Sedlmayer F, Wolf F, Zamboglou C, Zips D, Wiegel T.
Radiotherapy in nodal oligorecurrent prostate cancer.
Strahlenther Onkol. 2021 Jul;197(7):575-580. doi: 10.1007/s00066-021-01778-1.

Scharl S, Hadaschik B, Wiegel T, Thomas C.
[Treatment of primary oligometastatic prostate cancer].
Urologe A. 2021 Dec;60(12):1527-1533. doi: 10.1007/s00120-021-01643-0.

Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Bütof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Löck S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pöttgen C, Rödel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zöphel K, Zschaeck S, Thorwarth D, Troost EGC; Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN.
Value of PET imaging for radiation therapy.
Strahlenther Onkol. 2021 Sep;197(9):1-23. doi: 10.1007/s00066-021-01812-2.

Höcht S, Mason M, Wiegel T.
Timing of ADT in Radiotherapy of Prostate Cancer.
J Clin Oncol. 2021 Jul 10;39(20):2315-2316. doi: 10.1200/JCO.21.00032.

Püllen L, Sprave T, Hadaschik B, Wiegel T.
[Local and metastasis-directed therapy for oligometastatic prostate cancer].
Aktuelle Urol. 2021 Apr;52(2):149-154. doi: 10.1055/a-1328-9975.

Knipper S, Ott S, Schlemmer HP, Grimm MO, Graefen M, Wiegel T.
Options for Curative Treatment of Localized Prostate Cancer.
Dtsch Arztebl Int. 2021 Apr 2;118(Forthcoming):228-36. doi: 10.3238/arztebl.m2021.0026.

Bottke D, Miksch J, Thamm R, Krohn T, Bartkowiak D, Beer M, Bolenz C, Beer AJ, Prasad V, Wiegel T.
Changes of Radiation Treatment Concept Based on ⁶⁸Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy.
Front Oncol. 2021 Jun 1;11:665304. doi: 10.3389/fonc.2021.665304.

Lardas M, Grivas N, Debray TPA, Zattoni F, Berridge C, Cumberbatch M, Van den Broeck T, Briers E, De Santis M, Farolfi A, Fossati N, Gandaglia G, Gillessen S, O'Hanlon S, Henry A, Liew M, Mason M, Moris L, Oprea-Lager D, Ploussard G, Rouviere O, Schoots IG, van der Kwast T, van der Poel H, Wiegel T, Willemse PP, Yuan CY, Grummet JP, Tilki D, van den Bergh RCN, Lam TB, Cornford P, Mottet N.
Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2021 May 6:S2405-4569(21)00126-7. doi: 10.1016/j.euf.2021.04.020.

Moris L, Gandaglia G, Vilaseca A, Van den Broeck T, Briers E, De Santis M, Gillessen S, Grivas N, O'Hanlon S, Henry A, Lam TB, Lardas M, Mason M, Oprea-Lager D, Ploussard G, Rouviere O, Schoots IG, van der Poel H, Wiegel T, Willemse PP, Yuan CY, Grummet JP, Tilki D, van den Bergh RCN, Cornford P, Mottet N.
Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review.          Eur Urol Focus. 2021 Jun 16:S2405-4569(21)00161-9. doi: 10.1016/j.euf.2021.05.009

Bates AS, Ayers J, Kostakopoulos N, Lumsden T, Schoots IG, Willemse PM, Yuan Y, van den Bergh RCN, Grummet JP, van der Poel HG, Rouvière O, Moris L, Cumberbatch MG, Lardas M, Liew M, Van den Broeck T, Gandaglia G, Fossati N, Briers E, De Santis M, Fanti S, Gillessen S, Oprea-Lager DE, Ploussard G, Henry AM, Tilki D, van der Kwast TH, Wiegel T, N'Dow J, Mason MD, Cornford P, Mottet N, Lam TBL.
A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research.
Eur Urol Oncol. 2021 Jun;4(3):405-423. doi: 10.1016/j.euo.2020.12.008.

Schmidt-Hegemann NS, Zamboglou C, Thamm R, Eze C, Kirste S, Spohn S, Li M, Stief C, Bolenz C, Schultze-Seemann W, Bartenstein P, Prasad V, Ganswindt U, Grosu AL, Belka C, Mayer B, Wiegel T. A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa.
Front Oncol. 2021 Oct 1;11:723536. doi: 10.3389/fonc.2021.723536. eCollection 2021

Zamboglou C, Spohn SKB, Adebahr S, Huber M, Kirste S, Sprave T, Gratzke C, Chen RC, Carl EG, Weber WA, Mix M, Benndorf M, Wiegel T, Baltas D, Jenkner C, Grosu AL.
PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial.
Cancers (Basel). 2021 Nov 18;13(22):5795. doi: 10.3390/cancers13225795.

Shelan M, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Schmidt-Hegemann NS, Sedlmayer F, Wolf F, Zamboglou C, Zips D, Wiegel T, Ghadjar P.
Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries : A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO).
Strahlenther Onkol. 2021 Nov;197(11):993-1000. doi: 10.1007/s00066-021-01820-2. Epub 2021 Aug 31.

Van den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D, De Santis M, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Mason M, Moris L, Schoots IG, van der Kwast T, van der Poel H, Wiegel T, Willemse PM, Rouvière O, Lam TB, Mottet N. Eur Urol Focus. 2020 Mar 15;6(2):231-234. doi: 10.1016/j.euf.2019.06.004. Epub 2019 Jun 24Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations.

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Der Heijden AGV, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol. 2020 Feb;77(2):223-250.

Moris L, Cumberbatch MG, Van den Broeck T, Gandaglia G, Fossati N, Kelly B, Pal R, Briers E, Cornford P, De Santis M, Fanti S, Gillessen S, Grummet JP, Henry AM, Lam TBL, Lardas M, Liew M, Mason MD, Omar MI, Rouvière O, Schoots IG, Tilki D, van den Bergh RCN, van Der Kwast TH, van Der Poel HG, Willemse PM, Yuan CY, Konety B, Dorff T, Jain S, Mottet N, Wiegel T., Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol. 2020 May;77(5):614-627. doi: 10.1016/j.eururo.2020.01.033. Epub 2020 Mar 4. PMID: 32146018 Review.

Beck M, Böhmer D, Aebersold DM, Albrecht C, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Zschaeck S, Budach V, Wiegel T, Ghadjar P; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO). Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer : Statement from the DEGRO working group on prostate cancer. Strahlenther Onkol. 2020 Feb;196(2):109-116. doi: 10.1007/s00066-019-01553-3. Epub 2019 Nov 29

Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Wiegel T; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and The Working Party Radiation Oncology of the German Cancer Society (DKG-ARO). Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer Strahlenther Onkol. 2020 Jul;196(7):589-597. doi: 10.1007/s00066-020-01598-9. Epub 2020 Mar 12

Miksch J, Bottke D, Krohn T, Thamm R, Bartkowiak D, Solbach C, Bolenz C, Beer M, Wiegel T, Beer AJ, Prasad V., Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy.Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2339-2347. doi: 10.1007/s00259-020-04718-w. Epub 2020 Mar 10

Ghadjar P, Wiegel T., Androgen deprivation therapy plus salvage radiotherapy after prostatectomy. Lancet Oncol. 2020 Jan;21(1):e11. doi: 10.1016/S1470-2045(19)30730-2.

Ghadjar P, Böhmer D, Höcht S, Sedlmayer F, Wiegel T., Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer. J Clin Oncol. 2020 May 20;38(15):1746. doi: 10.1200/JCO.20.00149. Epub 2020 Mar 25

Bottke D, Wiegel T., [Treatment of the primary tumour in oligometastatic prostate cancer]. Aktuelle Urol. 2020 Jun;51(3):252-257. doi: 10.1055/a-1118-1991. Epub 2020 May 5

König L, Herfarth K, Hörner-Rieber J, Dietrich S, Wiegel T, Debus J, Viardot A., Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma. Strahlenther Onkol. 2020 Aug;196(8):705-714. doi: 10.1007/s00066-020-01624-w. Epub 2020 May 6

Cornford P, van den Bergh RCN, Briers E, den Broeck TV, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, der Kwast THV, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, der Poel HGV, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Mottet N., EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer,  Eur Urol. 2020 Oct 7:S0302-2838(20)30773-9. doi: 10.1016/j.eururo.2020.09.046. Online ahead of print

Bartkowiak D, Thamm R, Siegmann A, Böhmer D, Budachb V, Wiegel T., Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer,  Radiother Oncol. 2020 Sep 10:S0167-8140(20)30781-7. doi: 10.1016/j.radonc.2020.09.009. Online ahead of print

Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M., Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial),  J Cancer Res Clin Oncol. 2020 Sep 4. doi: 10.1007/s00432-020-03327-2. Online ahead of print.

Albers P, Wiegel T, Schmidberger H, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Meisner C, Wellek S, Grozinger K, Renner P, Burmester M, Schneider F, Stöckle M., Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial,  World J Urol. 2020 Mar 18. doi: 10.1007/s00345-020-03154-7. Online ahead of print

Böhmer D, Höcht S, Wiegel T., Moving Beyond the Hazard Ratio to Personalized Therapy: Is it Prime Time?, Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):903-904. doi: 10.1016/j.ijrobp.2020.08.022.

Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P.EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7

Martini A, Fossati N, Karnes RJ, Boorjian SA, Boeri L, Bossi A, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Robesti D, Bartkowiak D, Böhmer D, Shariat SF, Goldner G, Battaglia A, Joniau S, Berghen C, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, Briganti A. Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. Eur Urol Oncol 2019;S2588-9311(19)30162-2.

Beck M, Böhmer D, Aebersold DM, Albrecht C, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller A-C, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Zschaeck S, Budach V, Wiegel T, Ghadjar P, Prostate Cancer Expert Panel of the German Society of Radiation O, the Working Party Radiation Oncology of the German Cancer S. Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer : Statement from the DEGRO working group on prostate cancer. Strahlenther Onkol 2019;10.1007/s00066-019-1553-3.

Horwich A, Babjuk M, Bellmunt J, Bruins HM, Reijke TMD, Santis MD, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Kwast TVD, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, Bari BD, Blok WD, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Ann Oncol. 2019;30(11):1697–1727.

Ghadjar P, Wiegel T. Re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur Urol. In press. dx.doi.org/10.1016/j.eururo.2019.07.009. Eur Urol 2019;S0302-2838(19)30841-3.

Herfarth K, Borchmann P, Schnaidt S, Hohloch K, Budach V, Engelhard M, Viardot A, Engenhart-Cabillic R, Keller U, Reinartz G, Eich H-T, Witzens-Harig M, Hess CF, Dörken B, Dürig J, Wiegel T, Hiddemann W, Hoster E, Pott C, Dreyling M. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study. HemaSphere 2018;2(6):e160-e.

Ott S, Wiegel T, Hoffmann TK, Petersen C, Tribius S, Laban S. Studies on radiotherapy of head and neck cancer : Highlights of the 2019 ASCO Annual Meeting. HNO 2019;67(12):918-24.

Lam TBL, MacLennan S, Willemse P-PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH, Bjartell A, Bossi A, Briers E, Briganti A, Buddingh KT, Catto JWF, Colecchia M, Cox BW, Cumberbatch MG, Davies J, Davis NF, De Santis M, Dell'Oglio P, Deschamps A, Donaldson JF, Egawa S, Fankhauser CD, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Gross T, Grummet JP, Henry AM, Ingels A, Irani J, Lardas M, Liew M, Lin DW, Moris L, Omar MI, Pang KH, Paterson CC, Renard-Penna R, Ribal MJ, Roobol MJ, Rouprêt M, Rouvière O, Sancho Pardo G, Richenberg J, Schoots IG, Sedelaar JPM, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, van Leenders GJLH, Varma M, Violette PD, Wallis CJD, Wiegel T, Wilkinson K, Zattoni F, N'Dow JMO, Van Poppel H, Cornford P, Mottet N. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur Urol 2019;76(6):790-813.

Dirix PR, Dal Pra A, Wiegel T. Re: Gaëtan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol 2019;76:265-7. European urology 2019;76(5):e148-e9.

Van den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D, De Santis M, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Mason M, Moris L, Schoots IG, van der Kwast T, van der Poel H, Wiegel T, Willemse P-PM, Rouvière O, Lam TB, Mottet N. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur Urol Focus 2019;S2405-4569(19)30159-2.

Bartkowiak D, Siegmann A, Böhmer D, Budach V, Wiegel T. The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer. BJU Int 2019;124(5):785-91.

Böhmer D, Sedlmayer F, Wiegel T, Wolf F. Primary radiotherapy and short androgen deprivation therapy of 18 months may be sufficient in patients with localized prostate cancer with high-risk-factor compared to the standard of 28 to 36 months. Strahlenther Onkol 2019;195(8):764-6.

Bolla M, Henry A, Mason M, Wiegel T. The role of radiotherapy in localised and locally advanced prostate cancer. Asian journal of urology 2019;6(2):153-61.

Wirth M, Fossati N, Albers P, Bangma C, Brausi M, Comperat E, Faithfull S, Gillessen S, Jereczek-Fossa BA, Mastris K, Mottet N, Müller SC, Pieters B, Ribal MJ, Sangar V, Schoots IG, Smelov V, Travado L, Valdagni R, Wesselmann S, Wiegel T, van Poppel H. The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. European urology 2019;76(2):179-86.

Fossati N, Robesti D, Karnes RJ, Soligo M, Boorjian SA, Bossi A, Coraggio G, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Scarcella S, Bartkowiak D, Böhmer D, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, Briganti A. Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. Eur Urol 2019;76(4):443-9.

Ghadjar P, Wiegel T. Re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31. European urology 2019;75(3):e61-e2.

Bottke D, Bartkowiak D, Siegmann A, Thamm R, Böhmer D, Budach V, Wiegel T. Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. Prostate Cancer Prostatic Dis 2019;22(2):344-9.

Lam TBL, MacLennan S, Plass K, Willemse P-PM, Mason MD, Cornford P, Donaldson J, Davis NF, Dell'Oglio P, Fankhauser C, Grivas N, Ingels A, Lardas M, Liew M, Pang KH, Paterson C, Omar MI, Zattoni F, Buddingh KT, Van den Broeck T, Cumberbatch MG, Fossati N, Gross T, Moris L, Schoots IG, van den Bergh RCN, Briers E, Fanti S, De Santis M, Gillessen S, Grummet JP, Henry AM, van der Poel HG, van der Kwast TH, Rouvière O, Tilki D, Wiegel T, N'Dow J, Van Poppel H, Mottet N. Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. Eur Urol 2019;75(4):699-702.

Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, Cumberbatch M, De Santis M, Tilki D, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Rouvière O, Pecanka J, Mason MD, Schoots IG, van Der Kwast TH, van Der Poel HG, Wiegel T, Willemse P-PM, Yuan Y, Lam TB, Cornford P, Mottet N. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol 2019;75(6):967-87.

van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry AM, Lam TB, Mason MD, Rouvière O, De Santis M, Wiegel T, Willemse P-PM, van Poppel H, Mottet N. Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2019;75(2):e23-e4.

Ott S, Albrecht S, Friedl T, Gut S, Bartkowiak D, Janni W, Schwentner L, Bekes I, Thamm R, Wiegel T, Fink V. Cosmetic Results of Intraoperative Radiotherapy (IORT) in Mammary-Ca. Strahlenther Onkol 2019; 195 (Suppl.1):S146-7.

Wiegel T, Graefen M. Prostate Cancer. Onkologe 2019;25(4):290-3.

Mandel P, Theissen L, Schlomm T, Wiegel T, Hammerer P, Graefen M. Radical prostatectomy in locally advanced and metastatic prostate cancer. Onkologe 2019;25(4):315-21

Beck M, Bohmer D, Höcht S, Zschaeck S, Budach V, Wiegel T, Ghadjar P. Intermediate-risk profile in prostate cancer. Role of combined radiation and hormone therapy. Onkologe 2019;25(4):322-29

Bottke D, Bohmer D, Höcht S, Schmidt-Hegemann NS, Ott S, Ganswindt U, Bolenz C, Wiegel T. Role of combined ADT and salvage radiation therapy after radical prostatectomy in primary pN0-stage. Onkologe 2019;25(4):330-7.

Ott S, Wiegel T, Laban S, Hoffmann TK, Petersen C, Tribius S. [Radiotherapeutic studies of head and neck cancer-highlights of the 2018 ASCO Annual Meeting]. HNO. 2018 Dec;66(12):901-906.

Ghadjar P, Wiegel T. Optimizing radiotherapy for intermediate-risk localized disease. Nat Rev Urol. 2018 Aug;15(8):470-471.

Fossati N, Parker WP, Karnes RJ, Colicchia M, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Bartkowiak D, Wiegel T, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A, Boorjian SA.  More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. Eur Urol. 2018 Aug;74(2):134-137.

Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Sedlmayer F, Wenz F, Zips D, Wiegel T; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO). Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Strahlenther Onkol. 2018 Jul;194(7):619-626.

Lohm G, Neumann K, Budach V, Wiegel T, Hoecht S, Gollrad J. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression. Strahlenther Onkol. 2018 Apr;194(4):325-332.

Bartkowiak D, Thamm R, Bottke D, Siegmann A, Böhmer D, Budach V, Wiegel T. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. Acta Oncol. 2018 Mar;57(3):362-367.

Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A.  Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. Eur Urol. 2018 Apr;73(4):512-518.

Ghadjar P, Wiegel T. Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol 2018;73:156–65

Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A. Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. Eur Urol. 2018 Mar;73(3):436–444

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 Mar;73(3):436–444

Ghadjar P, Wiegel T. Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. In press. dx.doi.org/10.1016/j.eururo.2017.06.027.Eur Urol. 2017 Oct 19. pii: S0302-2838(17)30861-8. doi: 10.1016/j.eururo.2017.10.005. [Epub ahead of print]

Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A. Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. Eur Urol. 2017 Aug 2. pii: S0302-2838(17)30655-3. doi: 10.1016/j.eururo.2017.07.026. [Epub ahead of print]

Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, Cornford P, Cumberbatch MG, Fossati N, Gross T, Henry AM, Bolla M, Briers E, Joniau S, Lam TB, Mason MD, Mottet N, van der Poel HG, Rouvière O, Schoots IG, Wiegel T, Willemse PM, Yuan CY, Bourke L. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Eur Urol. 2017 Dec;72(6):869-885.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2017 Jun 24. pii: S0302-2838(17)30497-9. doi: 10.1016/j.eururo.2017.06.002. [Epub ahead of print]

Budäus L, Schiffmann J, Graefen M, Huland H, Tennstedt P, Siegmann A, Böhmer D, Budach V, Bartkowiak D, Wiegel T. Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate. Strahlenther Onkol. 2017 Sep;193(9):692-699.

Wollschläger D, Merzenich H, Schwentner L, Janni W, Wiegel T, Bartkowiak D, Wöckel A, Schmidt M, Schmidberger H, Blettner M. Self-reported long-term cardiac morbidity in breast cancer patients: a retrospective cohort study in Germany (PASSOS Heart Study). Breast Cancer Res Treat. 2017 Jun;163(3):595-604

Bottke D, Bolenz C, Ott S, Cebulla A, Wiegel T. [When should the primary tumor of metastatic bladder or prostate cancer be treated using a nonsurgical regimen?] Urologe A. 2017 May;56(5):579-584.

MacLennan S, Williamson PR, Bekema H, Campbell M, Ramsay C, N'Dow J, MacLennan S, Vale L, Dahm P, Mottet N, Lam T; COMPACTERS study group., Abel P, Ahmed HU, Akehurst G, Almquist R, Beck K, Budd D, Canfield S, Catto J, Cornford P, Cross W, Ewen A, Grant J, Heer R, Hurst D, Jones R, Kockelbergh R, Mackie A, MacDonald G, McNeill A, Mason M, McClinton S, McLaren D, Mostafid H, Pearce I, Pennet L, Royle J, Schreuder H, Stewart GD, van der Poel H, Wardlaw K, Wiegel T.  A core outcome set for localised prostate cancer effectiveness trials. BJU Int. 2017 Nov;120(5B):E64-E79.

Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RC, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017 Aug;72(2):250-266

Hoffmann TK, Schuler PJ, Laban S, Grässlin R, Beer M, Beer AJ, Friebe-Hoffmann U, Bullinger L, Möller P, Wiegel T. Response Evaluation in Head and Neck Oncology: Definition and Prediction. ORL J Otorhinolaryngol Relat Spec. 2017;79(1-2):14-23.

Fossati N, Willemse PM, van den Bergh RC, Van den Broeck T, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol. 2017 Jul;72(1):84-109.

Wollschläger D, Karle H, Stockinger M, Bartkowiak D, Bührdel S, Merzenich H, Wiegel T, Schmidberger H, Blettner M. Predicting Heart Dose in Breast Cancer Patients Who Received 3D Conformal Radiation Therapy. Health Phys. 2017 Jan;112(1):1-10.

Merzenich H, Bartkowiak D, Schmidberger H, Schmidt M, Schwentner L, Wiegel T, Woeckel A, Wollschläger D, Blettner M. 3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study). Breast Cancer Res Treat. 2017 Jan;161(1):143-152.

Höcht S, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Hölscher T, Martin T, Sedlmayer F, Wenz F, Zips D, Wiegel T. Hypofractionated radiotherapy for localized prostate cancer. Strahlenther Onkol. 2017 Jan;193(1):1-12

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017 Apr;71(4):630-642.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618-629

Fossati N, Karnes RJ, Boorjian SA, Moschini M, Morlacco A, Bossi A, Seisen T, Cozzarini C, Fiorino C, Chiorda BN, Gandaglia G, Dell'Oglio P, Joniau S, Tosco L, Shariat S, Goldner G, Hinkelbein W, Bartkowiak D, Haustermans K, Tombal B, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. Eur Urol. 2017 Jun;71(6):886-893

van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. Eur Urol. 2016 May;69(5):802-20.

Fiorino C, Broggi S, Fossati N, Cozzarini C, Goldner G, Wiegel T, Hinkelbein W, Karnes RJ, Boorjian SA, Haustermans K, Joniau S, Palorini F, Shariat S, Montorsi F, Van Poppel H, Di Muzio N, Calandrino R, Briganti A. Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in ≥PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):333-40

Bartkowiak D. AUO. Adjuvante Strahlentherapie nach radikaler Prostatektomie. Aktuelle Urol. 2016 Feb;47(1):22-4.

Ebner F, Schramm A, Bottke D, Friedl TW, Wiegel T, Fink V, Lato K, Bekes I, Janni W, de Gregorio N. Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost. Arch Gynecol Obstet. 2016 Oct;294(4):861-6

Kowalski C, Ferencz J, Albers P, Fichtner J, Wiegel T, Feick G, Wesselmann S. Quality assessment in prostate cancer centers certified by the German Cancer Society. World J Urol. 2016 May;34(5):665-72.

Böhmer D, Wirth M, Miller K, Budach V, Heidenreich A, Wiegel T. Radiotherapy and Hormone Treatment in Prostate Cancer. Dtsch Arztebl Int. 2016 Apr 8;113(14):235-41

Bottke D, Bartkowiak D, Bolenz C, Wiegel T. [Radiotherapy in node-positive prostate cancer]. Urologe A. 2016 Mar;55(3):345-9.

Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. Eur Urol. 2016 Apr;69(4):728-33.

Breul J, Wiegel T. Radiotherapy vs. radical surgery. Urologe A. 2016 Mar;55(3):311-2.

Ohlmann CH, Stöckle M, Albers P, Schmidberger H, Härter M, Kristiansen G, Martus P, Wellek S, Bussar-Maatz R, Wiegel T. PREFERE - Study on the rise. Urologe A. 2016 Mar;55(3):313-7.

Wollschläger D, Karle H, Stockinger M, Bartkowiak D, Bührdel S, Merzenich H, Wiegel T, Blettner M, Schmidberger H. Radiation dose distribution in functional heart regions from tangential breast cancer radiotherapy. Radiother Oncol. 2016 Apr;119(1):65-70.

Bartkowiak D, Bottke D, Thamm R, Siegmann A, Hinkelbein W, Wiegel T. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival. Radiother Oncol. 2016 Jan;118(1):131-5.

van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.Eur Urol. 2015 Dec 12. pii: S0302-2838(15)01178-1. doi: 10.1016/j.eururo.2015.11.023. [Epub ahead of print]

Rexer H, Bartkowiak D. Adjuvant radiotherapy in lymph-node-positive prostate cancer with low tumor burden after radical prostatectomy : Multicenter randomized phase III trial on the effect of adjuvant radio therapy in patients with prostate cancer with or without positive margins after radical prostatectomy (RP) and lymph node metastasis with low tumor burden (micrometastases, ≤ 2 lymph node macrometastases). ART-2 trial AP 61/11 of the AUO. Urologe A. 2015 Jun;54(6):871-4. doi: 10.1007/s00120-015-3824-1.

Bossi A, Wiegel T, Roach M. Postprostatectomy Radiotherapy for Patients with High-risk Features on Definitive Pathology: A Plea for Evidence-based Medicine. Eur Urol. 2015 Nov;68(5):775-6.

Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.

ICECaP Working Group. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst. 2015 Sep 25;107(12).

Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A: Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. Eur Urol. 2015 Oct 20. [Epub ahead of print]

Kowalski C, Ferencz J, Albers P, Fichtner J, Wiegel T, Feick G, Wesselmann S. Quality assessment in prostate cancer centers certified by the German Cancer Society. World J Urol. 2015 Sep 21. [Epub ahead of print]

Karl A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, Ganzer R, Wieland W, Eder F, Hofstädter F, Schilling D, Sievert KD, Stenzl A, Scharpf M, Fend F, Vom Dorp F, Rübben H, Kurt Werner S, Porres-Knoblauch D, Heidenreich A, Hangarter B, Knüchel-Clarke R, Rogenhofer M, Wullich B, Hartmann A, Comploj E, Pycha A, Hanspeter E, Pehrke D, Sauter G, Graefen M, Gratzke C, Stief C, Wiegel T, Haese A. Risk and timing of biochemical recurrence in pT3aN0/Nx prostate cancer with positive surgical margin - A multicenter study. Radiother Oncol. 2015 Jul;116(1):119-24

Valdagni R, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, Brausi M, Denis L, Drudge-Coates L, De Santis M, Feick G, Harrison C, Haustermans K, Hollywood D, Hoyer M, Hummel H, Mason M, Mirone V, Müller SC, Parker C, Saghatchian M, Sternberg CN, Tombal B, van Muilekom E, Watson M, Wesselmann S, Wiegel T, Magnani T, Costa A. Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. Crit Rev Oncol Hematol. 2015 Aug;95(2):133-43.

Sänger S, Wiegel T, Stöckle M, Härter M, Bergelt C.  [Development of patient education materials for the "German Prostate Cancer Trial PREFERE"]. Z Evid Fortbild Qual Gesundhwes. 2015;109(1):28-39.

Bartkowiak D, Schrader AJ, Wiegel T. [Adjuvant vs. salvage radiotherapy after radical prostatectomy]. Aktuelle Urol. 2015 Jan;46(1):52-8.

Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94.

Wiegel T, Stöckle M, Bartkowiak D. PREFEREnce-based randomized evaluation of treatment modalities in low or early intermediate-risk prostate cancer. Eur Urol. 2015 Jan;67(1):1-2.

Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, Blute M, Catto J, Chen RC, D'Amico AV, Feick G, Fitzpatrick JM, Frank SJ, Froehner M, Frydenberg M, Glaser A, Graefen M, Hamstra D, Kibel A, Mendenhall N, Moretti K, Ramon J, Roos I, Sandler H, Sullivan FJ, Swanson D, Tewari A, Vickers A, Wiegel T, Huland H. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol. 2015 Mar;67(3):460-7.

Fizazi K, Abrahamsson PA, Ahlgren G, Bellmunt J, Castellano D, Culine S, de Wit R, Gillessen S, Gschwend JE, Hamdy F, James N, McDermott R, Miller K, Wiegel T, Wirth M, Tombal B. Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. Eur Urol. 2015 May;67(5):904-12.

Koontz BF, Bossi A, Cozzarini C, Wiegel T, D'Amico A. A Systematic Review of Hypofractionation for Primary Management of Prostate Cancer. Eur Urol. 2015 Oct;68(4):683-91.

Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium, and the CENTRIC study team. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep;15(10):1100-8.

Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; on behalf of the ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8

Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Stöckle M, Rübe C, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K. Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96-02/AUO AP 09/95 Trial. Eur Urol. 2014 Aug;66(2):243-50.

Lohm G, Lütcke J, Jamil B, Höcht S, Neumann K, Hinkelbein W, Wiegel T, Bottke D. Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy : Long-term follow-up of a single-center survey. Strahlenther Onkol. 2014 Aug;190(8):727-31.

Wöckel A, Wolters R, Wiegel T, Novopashenny I, Janni W, Kreienberg R, Wischnewsky M, Schwentner L; BRENDA study group. The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects. Ann Oncol. 2014 Mar;25(3):628-32.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol. 2014 Feb;65(2):467-79.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent-Update 2013. Eur Urol. 2014 Jan;65(1):124-37.

Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ: Early Salvage Radiotherapy Following Radical Prostatectomy. Eur Urol. 2014 Jun;65(6):1034-43.

Briganti A, Joniau S, Gandaglia G, Cozzarini C, Sun M, Tombal B, Haustermans K, Hinkelbein W, Shariat SF, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies. Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):960-7.

Kristiansen G, Stöckle M, Albers P, Schmidberger H, Martus P, Wellek S, Härter M, Bussar-Maatz R, Wiegel T. [The importance of pathology in the German prostate cancer study PREFERE]. Pathologe. 2013 Sep;34(5):449-62.

Baumunk D, Reunkoff R, Kushner J, Baumunk A, Kempkensteffen C, Steiner U, Weikert S, Moser L, Schrader M, Höcht S, Wiegel T, Miller K, Schostak M: Interdisciplinary decision making in prostate cancer therapy - 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin. BMC Med Inform Decis Mak. 2013 Aug 5;13:83.

Matuschek C, Bölke E, Belka C, Ganswindt U, Henke M, Stegmaier P, Bamberg M, Welz S, Debus J, Gioules A, Voigt A, Volk G, Ohmann C, Wiegel T, Budach V, Stuschke M, Schipper J, Gerber PA, Budach W: Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2013 Aug;189(8):625-631.

Fietkau R, Lewitzki V, Kuhnt T, Hölscher T, Hess CF, Berger B, Wiegel T, Rödel C, Niewald M, Hermann RM, Lubgan D: A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: Results of a randomized, controlled, multicenter trial. Cancer. 2013 Sep 15;119(18):3343-53.

Wiegel T, Albers P, Bussar-Maatz R, Gottberg A, Härter M, Kieser M, Kristiansen G, Nettekoven G, Martus P, Schmidberger H, Wellek S, Stöckle M. [PREFERE - the German prostatic cancer study : Questions and claims surrounding study initiation in January 2013]. Urologe A. 2013 Apr;52(4):576-9.

Bottke D, Golz R, Störkel S, Hinke A, Siegmann A, Hertle L, Miller K, Hinkelbein W, Wiegel T. Phase 3 Study of Adjuvant Radiotherapy Versus Wait and See in pT3 Prostate Cancer: Impact of Pathology Review on Analysis. Eur Urol. 2013 Aug;64(2):193-8.

Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V; Panel Members. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol. 2013 May;24(5):1141-62.

Mason M, Maldonado Pijoan X, Steidle C, Guerif S, Wiegel T, van der Meulen E, Bergqvist PB, Khoo V: Neoadjuvant Androgen Deprivation Therapy for Prostate Volume Reduction, Lower Urinary Tract Symptom Relief and Quality of Life Improvement in Men with Intermediate- to High-risk Prostate Cancer: A Randomised Non-inferiority Trial of Degarelix versus Goserelin plus Bicalutamide. Clin Oncol (R Coll Radiol). 2013 Mar;25(3):190-6.

Kornmann M, Staib L, Wiegel T, Kron M, Henne-Bruns D, Link KH, Formentini A; Study Group Oncology of Gastrointestinal Tumors (FOGT): Long-Term Results of 2 Adjuvant Trials Reveal Differences in Chemosensitivity and the Pattern of Metastases Between Colon Cancer and Rectal Cancer. Clin Colorectal Cancer. 2013 Mar;12(1):54-61.

Lohm G, Bottke D, Jamil B, Miller K, Neumann K, Bartkowiak D, Hinkelbein W, Wiegel T: Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results. World J Urol. 2013 Apr;31(2):423-8.

Bartkowiak D, Bottke D, Wiegel T. Adjuvant radiotherapy or early salvage radiotherapy in pT3R0 or pT3R1 prostate cancer. Curr Opin Urol. 2013 Jul;23(4):360-5.

Bartkowiak D, Bottke D, Wiegel T. Radiotherapy in the management of prostate cancer after radical prostatectomy. Future Oncol. 2013 May;9(5):669-79.

Bottke D, Bartkowiak D, Schrader M, Wiegel T: Radiotherapy after radical prostatectomy: immediate or early delayed? Strahlenther Onkol. 2012 Dec;188(12):1096-1101.

Briganti A, Wiegel T, Joniau S, Cozzarini C, Bianchi M, Sun M, Tombal B, Haustermans K, Budiharto T, Hinkelbein W, Di Muzio N, Karakiewicz PI, Montorsi F, Van Poppel H: Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol. 2012 Sep;62(3):472-87.

Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R; German Rectal Cancer Study Group: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012 Jul;13(7):679-87.

Budäus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, Wiegel T: Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol. 2012 Jan;61(1):112-27.

Siegmann A, Bottke D, Faehndrich J, Brachert M, Lohm G, Miller K, Bartkowiak D, Hinkelbein W, Wiegel T: Salvage radiotherapy after prostatectomy - what is the best time to treat? Radiother Oncol. 2012 May;103(2):239-43.

Bartkowiak D, Humble N, Suhr P, Hagg J, Mair K, Polivka B, Schneider U, Bottke D, Wiegel T. Second cancer after radiotherapy, 1981-2007. Radiother Oncol. 2012 Oct;105(1):122-6.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011 Jan;59(1):61-71.

Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V; ESMO Guidelines Working Group: Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep;22 Suppl 6:vi45-9.

Siegmann A, Bottke D, Faehndrich J, Lohm G, Miller K, Bartkowiak D, Wiegel T, Hinkelbein W: Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival : Results of a retrospective study. Strahlenther. Onkol. 2011,187:467-72.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F: EAU Guidelines on Prostate Cancer. Part I: Screening, Diagnosis, and Treatment of Clinically Localised Disease. Actas Urol Esp. 2011 Jul 12. [Epub ahead of print]

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Actas Urol. Esp. 2011 Jul 12. [Epub ahead of print]

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 2011,59:572-83.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease.
Eur Urol. 2010 Oct 28.  [Epub ahead of print]

Wenz F, Martin T, Böhmer D, Martens S, Sedlmayer F, Wirth M, Miller K, Heidenreich A, Schrader M, Hinkelbein W, Wiegel T. The German S3 Guideline Prostate Cancer : Aspects for the Radiation Oncologist.
Strahlenther Onkol. 2010;186:531-4

Kornmann M, Staib L, Wiegel T, Kreuser ED, Kron M, Baumann W, Henne-Bruns D, Link KH. Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-a.
Br J Cancer. 2010;103:1163-72.

Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
J Clin Oncol. 2010;28:4199-206.

Welte B, Suhr P, Bottke D, Bartkowiak D, Dörr W, Trott KR, Wiegel T. Second Malignancies in High-Dose Areas of Previous Tumor Radiotherapy.
Strahlenther Onkol. 2010;186:175-79.

Kilian HG, Kazda M, Király F, Kaufmann D, Kemkemer R, Bartkowiak D: On the structure-bounded growth processes in plant populations.
Cell Biochem Biophys. 2010;57:87-100.

Bottke D, WiegelT: Radiotherapy and Prostate Cancer: Quo Vadis?
Eur Urol. 2010;Suppl 9,394-400

Martin T, Wenz F, Böhmer D, Sedlmayer F, Hinkelbein W, Henkel TO, Miller K, Wiegel T: [Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy]
Urologe A. 2010 Feb;49(2):216-20.

Böhmer D, Wenz F, Martin T, Sedlmayr F, Hinkelbein W, Wiegel T: [Radiation therapy for prostate cancer in the new S3 guideline. Part 1: localized and locally advanced prostate cancer]
Urologe A. 2010 Feb;49(2):211-5.

Grimm MO, Thomas C, Fröhner M, Wiegel T, Heidenreich A, Thüroff JW, Wirth M: [Pelvic lymphadenectomy and radical prostatectomy. Recommendations of the German S3 guideline]
Urologe A. 2010 Feb;49(2):206-10.

Welte B, Suhr P, Bottke D, Bartkowiak D, Dörr W, Trott KR, Wiegel T: Second malignancies in high-dose areas of previous tumor radiotherapy.
Strahlenther Onkol. 2010 Mar;186(3):174-9.

Meisner J, Meyer A, Polivka B, Karstens JH, Bremer M: Outcome of moderately dosed radiosurgery for limited brain metastases. Report of a single-center experience.
Strahlenther Onkol. 2010 Feb;186(2):76-81.